Oral microbiota patterns in chronic and autoimmune pancreatitis
Official title: The Characteristics of Oral Microbiota in Chronic Pancreatitis and Autoimmune Pancreatitis
Run by Ruijin Hospital · NCT07015580 · Data updated 2026-11-12
We will sequence mouth bacteria to see if people with chronic pancreatitis or autoimmune pancreatitis have different oral microbiota.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 360 (estimated) |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai, China) |
| Status | Recruiting |
| Started | February 18, 2025 |
| Main results expected | February 28, 2026 |
| Study ends | February 28, 2026 |
| Registry record updated | June 11, 2025 |
| Trial ID | NCT07015580 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with diagnosed chronic pancreatitis or autoimmune pancreatitis who can give informed consent, are not pregnant or lactating, have not had recent digestive surgery, and have avoided antibiotics, immunosuppressants, and daily probiotics for at least 30 days.
✕Probably not a fit
People who recently used antibiotics or immunosuppressants, have other active gastrointestinal diseases, are pregnant or lactating, have malignancy, or have had prior digestive surgery are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will collect saliva and oral swab samples from people with chronic pancreatitis and autoimmune pancreatitis and use full-length 16S rRNA sequencing to profile their oral bacterial communities. Participants who used antibiotics or immunosuppressants within 30 days, have recent digestive surgery, are pregnant or lactating, have other gastrointestinal diseases, or take daily probiotics will be excluded. Researchers will analyze species composition, diversity measures, and specific taxa to identify patterns associated with pancreatitis subtypes and pancreatic disease. The work addresses a gap in prior research that has focused mostly on gut microbiota rather than the mouth.
Why it matters
Potential benefit: If successful, this could identify oral bacterial signatures that help with earlier diagnosis or risk stratification for pancreatic disease and guide future prevention or monitoring strategies.
How similar studies have gone: Prior studies have detected oral bacteria in pancreatic tissue and linked microbiota changes to pancreatic disease, but most work has focused on gut microbiota; studies directly profiling oral microbiota in pancreatitis are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * A dated and signed informed consent form cooperate to complete sample collection Exclusion Criteria: * Previous digestive system surgery; During pregnancy or lactation; Complicated with infectious diseases, malignant tumors or other digestive system diseases (such as inflammatory bowel disease, irritable bowel syndrome, abdominal diseases, gastroesophageal reflux, etc.); Antibiotics and immunosuppressive drugs were used within 30 days before sampling; Those who take probiotics daily.
Where it's running
-
Department of Gastroenterolog, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai, China, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing two techniques for accessing the bile duct in patients with biliary diseases
This study is testing two different methods for accessing the bile duct to see which one works better for patients with biliary diseases like cholangiocarcinoma and choledocholithiasis.
-
Developing a blood test for early diagnosis of pancreatic cancer
This study is trying to develop a simple blood test to help find pancreatic cancer early and track how well treatments are working for patients.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
-
Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer
This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.
-
Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer
This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.